

M62

Performance Standards for Susceptibility Testing of *Mycobacteria*, *Nocardia* spp., and Other Aerobic Actinomycetes

This document includes updated breakpoint and quality control tables for the Clinical and Laboratory Standards Institute susceptibility testing standard M24.

A CLSI supplement for global application.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org

Performance Standards for Susceptibility Testing of *Mycobacteria*, *Nocardia* spp., and Other Aerobic Actinomycetes

Gail L. Woods, MD
Nancy L. Wengenack, PhD, D(ABMM)
Grace Lin, MS
Barbara A. Brown-Elliott, MS, MT(ASCP)SM
Daniela Maria Cirillo, MD, PhD
Patricia S. Conville, MS, MT(ASCP)
Edward P. Desmond, PhD, D(ABMM)
Scott B. Killian, BS
Nicole M. Parrish, PhD, MHS, D(ABMM)
Richard Pfeltz, PhD
Elvira Richter, PhD
John D. Turnidge, MD, BS, FRACP, FRCPA, FASM

Abstract

Clinical and Laboratory Standards Institute document M62—*Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes* includes the minimal inhibitory concentrations and quality control ranges developed following the standards described in CLSI document M24.¹ The data in the tables are valid only when the methodology in CLSI document M24¹ is followed.

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes*. CLSI supplement M62 (ISBN 978-1-68440-027-0 [Print]; ISBN 978-1-68440-028-7 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2018.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.

Copyright ©2018 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes*. 1st ed. CLSI supplement M62. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.

Committee Membership

Document Development Committee on Antimycobacterial Susceptibility Testing

Gail L. Woods, MD
Chairholder
 Arkansas Children's Hospital
 USA

Barbara A. Brown-Elliott, MS,
 MT(ASCP)SM
 University of Texas Health Science
 Center at Tyler
 USA

Beverly Metchock, DrPH,
 D(ABMM)
 Centers for Disease Control and
 Prevention
 USA

Nancy L. Wengenack, PhD,
D(ABMM)
Vice-Chairholder
 Mayo Clinic
 USA

Daniela Maria Cirillo, MD, PhD
 WHO Collaborating Centre and TB
 Supranational Reference Laboratory
 Italy

Nicole M. Parrish, PhD, MHS,
 D(ABMM)
 Johns Hopkins Hospital - Pathology
 USA

Grace Lin, MS
Committee Secretary
 California Department of Public
 Health
 USA

Patricia S. Conville, MS, MT(ASCP)
 FDA Center for Devices and Radiological
 Health
 USA

Richard Pfeltz, PhD
 BD Life Sciences
 USA

Lynette Y. Berkeley, PhD, MT(ASCP)
 FDA Center for Drug Evaluation and
 Research
 USA

Edward P. Desmond, PhD, D(ABMM)
 California Department of Public Health
 USA

Elvira Richter, PhD
 Laboratory Limbach
 Germany

Scott B. Killian, BS
 Thermo Fisher Scientific
 USA

John D. Turnidge, MD, BS, FRACP,
 FRCPA, FASM
 University of Adelaide
 Australia

Staff

Clinical and Laboratory Standards
 Institute
 USA

Megan L. Tertel, MA, ELS
Editorial Manager

Kristy L. Leirer, MS
Editor

Marcy L. Hackenbrack, MCM,
 M(ASCP)
Project Manager

Catherine E.M. Jenkins
Editor

Laura Martin
Editor

Acknowledgment

CLSI and the Document Development Committee on Antimycobacterial Susceptibility Testing gratefully acknowledge the following volunteers for their important contributions to the development of this document:

Joan Miquel Balada-Llasat, PharmD,
 PhD, D(ABMM)
 Ohio State University Wexler
 Medical Center
 USA

Pennan Barry, MD, MPH
 California Department of Public Health
 USA

Janice Washington, MT(ASCP),
 MPH
 FDA Center for Devices and
 Radiological Health
 USA

Kone Kaniga, PhD
 Janssen Research and Development
 USA

Contents

Abstract.....	i
Committee Membership.....	iii
Overview of Changes.....	vii
Abbreviations and Acronyms	viii
Reference	ix
Table 1. Broth Microdilution Breakpoints and Interpretive Categories for MTBC Tested in Middlebrook 7H9 Broth Supplemented With OADC Using Commercially Available MIC Plates	1
Table 2. Susceptibility Testing of MTBC to Second-Line Drugs Using the Fluorescence-based Commercial Shorter-Incubation Liquid Media System	2
Table 3. Antimycobacterial Agents and Breakpoints for Testing MAC.....	4
Table 4. Antimycobacterial Agents and Breakpoints for Testing <i>M. kansasii</i>	5
Table 5. Antimycobacterial Agents and Breakpoints for Testing Slowly Growing Nontuberculous Mycobacteria Other Than MAC and <i>M. kansasii</i>	6
Table 6. Antimycobacterial Agents and Breakpoints for Testing Rapidly Growing Mycobacteria.....	7
Table 7. Antimycobacterial Agents and Breakpoints for Testing <i>Nocardia</i> spp. and Other Aerobic Actinomycetes.....	10
Table 8. Expected Antimicrobial Susceptibility Patterns of the Most Commonly Isolated <i>Nocardia</i> spp.....	12
Table 9. Expected Results for Routine and Supplemental QC Strains When Testing MTBC by a Culture-based Method.....	13
Table 10. MIC QC Ranges When Testing MTBC Using <i>M. tuberculosis</i> ATCC® 27294 (H37Rv) Tested in Middlebrook 7H9 Medium Supplemented With OADC	14
Table 11. QC Ranges for Susceptibility Testing of <i>M. tuberculosis</i> ATCC® 27294 (H37Rv) to Second-Line Drugs Using the Fluorescence-based Commercial Shorter-Incubation Liquid Media System	15
Table 12. Broth Microdilution QC Ranges When Testing Slowly Growing Nontuberculous Mycobacteria.....	16
Table 13. Broth Microdilution QC Ranges When Testing Rapidly Growing Mycobacteria.....	17
Table 14. Broth Microdilution QC Ranges When Testing <i>Nocardia</i> spp. and Other Aerobic Actinomycetes.....	18
The Quality Management System Approach	20
Related CLSI Reference Materials	21